Company / Accounts Receivable
TENAX THERAPEUTICS, INC. Accounts Receivable History
FY2012-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$72.6K
FY2016
5-year range
$36.4K / $72.6K
FY2012-FY2016
Trend
+99.7%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $36,358 to $72,599 over the past 2 years.
Based on SEC 10-K filings.
$72,599 in FY2016 with a 3-year CAGR of -45.4%.
Improved from $36,358 to $72,599 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -45.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -45.4%, indicating a declining trend.
- In FY2016, accounts receivable increased 99.7% year-over-year.
- Peak accounts receivable was recorded in FY2013.
- Lowest accounts receivable in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2016 | $72.6K | +99.7% |
| FY2015 | $36.4K | +0.0% |
| FY2014 | $36.4K | -91.8% |
| FY2013 | $445.2K | +3226.4% |
| FY2012 | $13.4K | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026